Drreddys Laboratories | RDY - Current Liabilities


Drreddys Laboratories reported INR167.57B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
ANI Pharmaceuticals USD 239.51M 38.6M Mar/2026
Aurora Cannabis CAD 66.93M 79M Mar/2026
Bayer EUR 33.46B 875M Mar/2026
Canopy Growth CAD 158.44M 60.15M Mar/2026
Cipla INR 70.14B 7.16B Mar/2026
Corcept Therapeutics USD 153.8M 4.62M Jun/2026
Drreddys Laboratories INR 167.57B 165.8B Mar/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Lonza CHF 3.57B 421M Dec/2025
Novartis USD 31.75B 374M Jun/2026
Pacira USD 122.01M 13.22M Jun/2026
Phibro Animal Health USD 281.87M 500K Mar/2026
Prestige Brands USD 120.92M 18.63M Mar/2026
Richter Gedeon HUF 179.31B 8.13B Mar/2026
Sun Pharmaceuticals INR 226.22B 7.93B Mar/2026
Supernus Pharmaceuticals USD 347.38M 26.55M Jun/2026
Teva Pharmaceutical Industries USD 15.65B 2.11B Jun/2026